Sec Form 4 Filing - Holles Natalie C. @ Audentes Therapeutics, Inc. - 2019-12-12

FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person Holles Natalie C. 2. Issuer Name and Ticker or Trading Symbol Audentes Therapeutics, Inc. [ BOLD] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director _____ 10% Owner X __ Officer (give title below) _____ Other (specify below) President and COO (Last) (First) (Middle) C/O AUDENTES THERAPEUTICS, INC., 600 CALIFORNIA STREET, 17TH FLOOR 3. Date of Earliest Transaction (MM/DD/YY) 12/12/2019 (Street) SAN FRANCISCO, CA94108 4. If Amendment, Date Original Filed (MM/DD/YY) 6. Individual or Joint/Group Filing (Check Applicable Line) __ X __ Form filed by One Reporting Person _____ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Common Stock ( 1 ) 12/12/2019 F( 2 ) 8,681 D $ 59.37 46,023 D Common Stock 12/12/2019 M 45,726 A $ 2.7649 91,749 D Common Stock 12/12/2019 M 5,715 A $ 9.4988 97,464 D Common Stock 12/12/2019 M 74,117 A $ 15.26 171,581 D Common stock 12/12/2019 M 6,891 A $ 27.39 178,472 D Common Stock 12/12/2019 M 14,895 A $ 24.74 193,367 D Common Stock 12/12/2019 F( 3 ) 88,928 D $ 59.37 104,439 D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares Stock Option (right to buy) $ 2.7649 12/12/2019 M 45,726 ( 4 ) 11/06/2025 Common Stock 45,726 $ 0 110,703 D Stock Option (right to buy) $ 9.4988 12/12/2019 M 5,715 ( 5 ) 12/18/2025 Common Stock 5,715 $ 0 548 D Stock Option (right to buy) $ 15.26 12/12/2019 M 74,117 ( 6 ) 01/25/2027 Common Stock 74,117 $ 0 40,883 D Stock Option (right to buy) $ 27.39 12/12/2019 M 6,891 ( 7 ) 11/16/2027 Common Stock 6,891 $ 0 93,109 D Stock Option (right to buy) $ 24.74 12/12/2019 M 14,895 ( 8 ) 02/06/2029 Common Stock 14,895 $ 0 50,105 D

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other Holles Natalie C. C/O AUDENTES THERAPEUTICS, INC. 600 CALIFORNIA STREET, 17TH FLOOR SAN FRANCISCO, CA94108 President and COO Signatures /s/ Mark Meltz, as Attorney-in-Fact for Natalie Holles 12/16/2019 Signature of Reporting Person Date

Explanation of Responses:

( 1 )On December 10, 2019, the Compensation Committee of the Issuer's Board of Directors approved the accelerated vesting and settlement of restricted stock units granted on February 6, 2019 in order to mitigate the potential adverse tax consequences of Sections 280G and 4999 of the Internal Revenue Code of 1986, as amended. ( 2 )Shares relinquished by the Reporting Person and cancelled by the Issuer in exchange for the Issuer's agreement to pay federal and state tax withholding obligations of the Reporting Person resulting from the vesting of restricted stock units. The Reporting Person did not sell or otherwise dispose of the shares for any reason other than to cover required taxes. ( 3 )Shares relinquished by the Reporting Person and cancelled by the Issuer in exchange for the Issuer's agreement to pay federal and state tax withholding obligations of the Reporting Person resulting from the exercise of stock options. The Reporting Person did not sell or otherwise dispose of the shares for any reason other than to cover required taxes. ( 4 )The option vests as to 25% of the total shares on August 17, 2016, and then 6.25% of the total shares vest quarterly thereafter, with 100% of the total shares vested and exercisable on August 17, 2019, subject to the reporting person's provision of service to the issuer on each vesting date. ( 5 )The option vests as to 6.25% of the total shares quarterly, beginning March 18, 2016, with 100% of the total shares vested and exercisable on December 18, 2019, subject to the reporting person's provision of service to the issuer on each vesting date and to accelerated vesting upon the occurrence of certain events. ( 6 )The option vests as to 2.0833% of the total shares monthly, beginning February 25, 2017, with 100% of the total shares vested and exercisable on January 25, 2021, subject to the reporting person's provision of service to the issuer on each vesting date. ( 7 )The option vests as to 2.0833% of the total shares monthly, beginning December 16, 2017, with 100% of the total shares vested and exercisable on November 16, 2021, subject to the reporting person's provision of service to the issuer on each vesting date. ( 8 )The option vests as to 2.0833% of the total shares monthly, beginning February 1, 2019, with 100% of the total shares vested and exercisable on January 1, 2023, subject to the reporting person's provision of service to the issuer on each vesting date.

Reminder: Report on a separate line for each class of securities beneficially owned directl y or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.